Biogen Reports Top-Line Results from Phase 3 Study Evaluating Natalizumab in Secondary Progressive MS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Leerink Partners Remains Bullish on Biogen (BIIB) Following 3Q Earnings Results
October 21, 2015 1:42 PM EDTLeerink Partners reiterated an Outperform rating and $425.00 price target on Biogen (NASDAQ: BIIB) following the company's 3Q15 earnings results. BIIB reported a 3Q beat on all top and bottom line levels. 3Q sales of 2.78 bn. vs. consensus estimates of $2.6B, 3Q non-GAAP EPS of 4.48 vs.... More
Cowen Remains Bullish as Biogen (BIIB) Reports 3Q EPS Beat
October 21, 2015 1:36 PM EDTCowen reiterated an Outperform rating and $368.00 price target on Biogen (NASDAQ: BIIB) following the company's 3Q15 earnings results. BIIB reported strong Q3 non-GAAP EPS of $4.48 vs. consensus of $3.84E, on revenue of $2.8B.
Analyst Eric Schmidt commented, "BIIB reported Q3 revenue and earnings well above... More
RBC Comments on Bull/Bear Case on Biogen (BIIB) Following Q3 Results
October 21, 2015 9:22 AM EDTRBC Capital maintained an Outperform rating on Biogen (NASDAQ: BIIB) with a price target of $450. Earlier Biogen reported Q3 results including a corporate restructuring and headcount reduction. In the view of analyst Michael J. Yee, this was relative good news against very low... More
Biogen's (BIIB) Phase 3 ASCEND Trial Missed Primary, Secondary Endpoints
October 21, 2015 7:32 AM EDTThe Phase 3 ASCEND study investigating natalizumab in the treatment of secondary progressive multiple sclerosis (SPMS) did not achieve its primary and secondary endpoints, Biogen (NASDAQ: BIIB) reported today. During the study, natalizumab was generally well tolerated and adverse events were consistent with its known safety profile.
ASCEND evaluated the efficacy and... More
Biogen (BIIB) Tops Q3 EPS by 68c; Announces Corp. Restructuring; Boosts FY15 EPS Outlook
October 21, 2015 7:31 AM EDTBiogen (NASDAQ: BIIB) reported Q3 EPS of $4.48, $0.68 better than the analyst estimate of $3.80. Revenue for the quarter came in at $2.39 billion versus the consensus estimate of $2.65 billion.
Corporate Restructuring
The Company plans to substantially complete the majority of the 11% reduction of its global workforce by the end of 2015. The Company is in the process of notifying employees affected by the restructuring, and... More
